Inhibrx Biosciences (NASDAQ:INBX) Receives Sell (D) Rating from Weiss Ratings

Inhibrx Biosciences (NASDAQ:INBX)‘s stock had its “sell (d)” rating reissued by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently issued reports on the company. JMP Securities restated a “market perform” rating on shares of Inhibrx Biosciences in a research report on Friday, August 22nd. Wall Street Zen upgraded Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Inhibrx Biosciences presently has an average rating of “Reduce”.

Inhibrx Biosciences Trading Up 0.3%

Shares of INBX stock opened at $33.61 on Wednesday. Inhibrx Biosciences has a 1 year low of $10.81 and a 1 year high of $37.53. The company has a debt-to-equity ratio of 1.45, a current ratio of 4.98 and a quick ratio of 4.98. The stock’s 50 day simple moving average is $27.16 and its two-hundred day simple moving average is $19.16. The company has a market cap of $486.67 million, a PE ratio of -3.18 and a beta of 0.51.

Inhibrx Biosciences (NASDAQ:INBX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($1.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.92) by $1.07. The company had revenue of $1.30 million for the quarter. Research analysts predict that Inhibrx Biosciences will post 104.88 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of INBX. Bank of America Corp DE bought a new position in Inhibrx Biosciences in the fourth quarter worth approximately $191,000. GAMMA Investing LLC grew its stake in Inhibrx Biosciences by 9,834.8% in the first quarter. GAMMA Investing LLC now owns 6,855 shares of the company’s stock worth $960,000 after purchasing an additional 6,786 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Inhibrx Biosciences by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 52,800 shares of the company’s stock worth $739,000 after purchasing an additional 1,355 shares in the last quarter. Tabor Asset Management LP bought a new position in Inhibrx Biosciences in the first quarter worth approximately $506,000. Finally, XTX Topco Ltd bought a new position in Inhibrx Biosciences in the first quarter worth approximately $237,000. Institutional investors own 82.46% of the company’s stock.

About Inhibrx Biosciences

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.